Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FBXW7_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FBXW7_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FBXW7_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FBXW7_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FBXW7_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FBXW7_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FBXW7_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FBXW7_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FBXW7_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FBXW7_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00313988 | Skin | AK | positive regulation of protein ubiquitination | 21/1910 | 119/18723 | 8.77e-03 | 4.32e-02 | 21 |
GO:00456383 | Skin | AK | negative regulation of myeloid cell differentiation | 17/1910 | 90/18723 | 8.93e-03 | 4.39e-02 | 17 |
GO:190288224 | Skin | AK | regulation of response to oxidative stress | 18/1910 | 98/18723 | 9.72e-03 | 4.72e-02 | 18 |
GO:2001233112 | Skin | SCCIS | regulation of apoptotic signaling pathway | 51/919 | 356/18723 | 5.51e-12 | 7.43e-09 | 51 |
GO:0042176112 | Skin | SCCIS | regulation of protein catabolic process | 54/919 | 391/18723 | 5.60e-12 | 7.43e-09 | 54 |
GO:0097193112 | Skin | SCCIS | intrinsic apoptotic signaling pathway | 42/919 | 288/18723 | 2.40e-10 | 2.12e-07 | 42 |
GO:1903362112 | Skin | SCCIS | regulation of cellular protein catabolic process | 38/919 | 255/18723 | 9.24e-10 | 5.45e-07 | 38 |
GO:2001242112 | Skin | SCCIS | regulation of intrinsic apoptotic signaling pathway | 28/919 | 164/18723 | 7.32e-09 | 2.95e-06 | 28 |
GO:0045732112 | Skin | SCCIS | positive regulation of protein catabolic process | 34/919 | 231/18723 | 9.75e-09 | 3.45e-06 | 34 |
GO:1903364112 | Skin | SCCIS | positive regulation of cellular protein catabolic process | 26/919 | 155/18723 | 3.64e-08 | 7.72e-06 | 26 |
GO:1903050112 | Skin | SCCIS | regulation of proteolysis involved in cellular protein catabolic process | 32/919 | 221/18723 | 3.93e-08 | 7.72e-06 | 32 |
GO:000268318 | Skin | SCCIS | negative regulation of immune system process | 49/919 | 434/18723 | 4.92e-08 | 8.19e-06 | 49 |
GO:2000058112 | Skin | SCCIS | regulation of ubiquitin-dependent protein catabolic process | 26/919 | 164/18723 | 1.18e-07 | 1.52e-05 | 26 |
GO:0010631110 | Skin | SCCIS | epithelial cell migration | 42/919 | 357/18723 | 1.45e-07 | 1.74e-05 | 42 |
GO:0050673110 | Skin | SCCIS | epithelial cell proliferation | 48/919 | 437/18723 | 1.56e-07 | 1.84e-05 | 48 |
GO:0045862112 | Skin | SCCIS | positive regulation of proteolysis | 43/919 | 372/18723 | 1.69e-07 | 1.91e-05 | 43 |
GO:0090132110 | Skin | SCCIS | epithelium migration | 42/919 | 360/18723 | 1.82e-07 | 1.97e-05 | 42 |
GO:0090130110 | Skin | SCCIS | tissue migration | 42/919 | 365/18723 | 2.66e-07 | 2.62e-05 | 42 |
GO:1903320112 | Skin | SCCIS | regulation of protein modification by small protein conjugation or removal | 32/919 | 242/18723 | 3.31e-07 | 3.03e-05 | 32 |
GO:190210516 | Skin | SCCIS | regulation of leukocyte differentiation | 35/919 | 279/18723 | 3.43e-07 | 3.03e-05 | 35 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXW7 | SNV | Missense_Mutation | | c.529N>C | p.Glu177Gln | p.E177Q | Q969H0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.058) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
FBXW7 | SNV | Missense_Mutation | rs866987936 | c.1436G>A | p.Arg479Gln | p.R479Q | Q969H0 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
FBXW7 | SNV | Missense_Mutation | | c.529G>C | p.Glu177Gln | p.E177Q | Q969H0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.058) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
FBXW7 | SNV | Missense_Mutation | | c.1625N>T | p.Asn542Ile | p.N542I | Q969H0 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
FBXW7 | SNV | Missense_Mutation | | c.902N>C | p.Leu301Pro | p.L301P | Q969H0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
FBXW7 | SNV | Missense_Mutation | novel | c.38N>T | p.Arg13Leu | p.R13L | Q969H0 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.931) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
FBXW7 | SNV | Missense_Mutation | | c.1634N>G | p.Tyr545Cys | p.Y545C | Q969H0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
FBXW7 | SNV | Missense_Mutation | novel | c.1195G>C | p.Asp399His | p.D399H | Q969H0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
FBXW7 | SNV | Missense_Mutation | | c.529N>A | p.Glu177Lys | p.E177K | Q969H0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.021) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
FBXW7 | SNV | Missense_Mutation | rs867384286 | c.1393N>T | p.Arg465Cys | p.R465C | Q969H0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | Docetaxel | DOCETAXEL | 23274910 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | Sirolimus | SIROLIMUS | 24586741,18787170,23558291 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | Vorinostat | VORINOSTAT | 23274910 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | AR-42 | AR-42 | 23274910 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | Regorafenib | REGORAFENIB | 27399335 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | Temsirolimus | TEMSIROLIMUS | 24360397 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | Entinostat | ENTINOSTAT | 23274910 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | SIROLIMUS | SIROLIMUS | 18787170 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | Belinostat | BELINOSTAT | 23274910 |
55294 | FBXW7 | DNA REPAIR, CLINICALLY ACTIONABLE | | MRK-003 | | 17646409 |